Cancer therapy shows long-term survival benefits for patients with high-risk, BRCA-positive breast cancer in trial
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
Medscape2d
Olaparib Continues to Protect Patients From High-Risk Cancer Recurrences
The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...
pharmaphorum2d
Lynparza boosts long-term survival in early breast cancer
AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
News Medical3d
Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Cure Today2d
Lynparza Continues to Benefit in BRCA1/2+, HER2- Breast Cancer
Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.
The Pharma Letter3d
Lynparza on a roll with early breast cancer win
Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...
pharmaphorum4d
MSD gets first positive trial of Keytruda/Lynparza combo
"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...
Targeted Oncology2d
6-Year Data Sustain Adjuvant Olaparib Benefit in BRCA1/2+, HER2- Breast Cancer
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...
Yahoo Finance3d
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
RAHWAY, N.J., December 11, 2024--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United ...
EurekAlert!3d
PARP inhibition shows long-term survival benefits for patients with high-risk, BRCA-positive breast cancer in OlympiA trial
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically ...